Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.celrep.2021.109450 http://scihub22266oqcxt.onion/10.1016/j.celrep.2021.109450 34289384!8270748!34289384     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Rep 2021 ; 36 (4): 109450 Nephropedia Template TP {{tp|p=34289384|t=2021. Prevention and therapy of SARS-CoV-2 and the B 1 351 variant in mice |pdf=|usr=}}{{34289384}} gab.com Text Prevention and therapy of SARS-CoV-2 and the B 1 351 variant in mice JO: Cell Rep http://www.kidney.de/pget.php?&tw=1&pmid=34289384 #FOAvip Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants. Twit Text FOAVip Prevention and therapy of SARS-CoV-2 and the B 1 351 variant in mice ????Cell Rep http://www.kidney.de/pget.php?&tw=1&pmid=34289384 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34289384 #FOAvip English Wikipedia <ref>{{Cite pmid|34289384}}</ref> Prevention and therapy of SARS-CoV-2 and the B 1 351 variant in mice #MMPMID34289384 Martinez DR; Schafer A; Leist SR; Li D; Gully K; Yount B; Feng JY; Bunyan E; Porter DP; Cihlar T; Montgomery SA; Haynes BF; Baric RS; Nussenzweig MC; Sheahan TP Cell Rep 2021[Jul]; 36 (4): 109450 PMID34289384show ga Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19). It is not known whether combination RDV/mAb will improve outcomes over single-agent therapies or whether antibody therapies will remain efficacious against variants. Here, we show that a combination of two mAbs in clinical trials, C144 and C135, have potent antiviral effects against even when initiated 48 h after infection and have therapeutic efficacy in vivo against the B.1.351 variant of concern (VOC). Combining RDV and antibodies provided a modest improvement in outcomes compared with single agents. These data support the continued use of RDV to treat SARS-CoV-2 infections and the continued clinical development of the C144 and C135 antibody combination to treat patients infected with SARS-CoV-2 variants. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antibodies, Monoclonal/immunology/*pharmacology[MESH] |Antiviral Agents/pharmacology[MESH] |Humans[MESH] |Mice[MESH]Prevention and therapy of SARS-CoV-2 and the B 1 351 variant in mice (epmc).pdf DeepDyve Pubget Overpricing